Association of anemia correction with health related quality of life in patients not on dialysis^*

References

• Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000;36:S39–1
   PubMed Web of Science ®Google Scholar
• Astor BC, Muntner P, Leviin A, et al. Association of kidney func tion with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2002;162:1401–8
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13: 504–10
   Google Scholar
• London R, Solis A, Goldberg GA, et al. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002;40:539–48
   PubMed Web of Science ®Google Scholar
• Obrador, GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001;60:1875–84
   Google Scholar
• Moreno F, Sanz-Guajardo D, López-Gómez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000;1:335–42
   Google Scholar
• Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. [see comment]. Am J Kidney Dis 1999;33:1122–30
   PubMed Web of Science ®Google Scholar
• McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999;14:1182–7
   PubMed Web of Science ®Google Scholar
• Benz RL, Pressman MR, Hovick ET, et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999;34:1089–95
   PubMed Web of Science ®Google Scholar
• Klang B, Bjorvell H, Clyne N. Quality of life in predialytic uremic patients. Qual Life Res 1996;5:109–16
   PubMed Web of Science ®Google Scholar
• Wolcott DL, Marsh JT, La Rue A, et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients; Am J Kidney Dis 1989;14:478–85
   Google Scholar
• Bergner M, Bobbitt RA, Kressel S, et al. The sickness impact profile: conceptual formulation and methodology for the develop ment of a health status measure. Int J Health Serv 1976;6:393–415
   PubMed Web of Science ®Google Scholar
• Hunt SM, McEwen J, McKenna SP, et al. Subjective health assess ments and the perceived outcome of minor surgery. J Psychosom Res 1984;28:105–14
   PubMed Web of Science ®Google Scholar
• Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey SF-36. I. conceptual framework and item selection. Med Care 1992;30:473–83
   Google Scholar
• Ware JEJ, Snow KK, Kosinski M. SF-36 Health Survey: Manual and Interpretation Guide. 2000, Lincoln, RI: QualityMetric Incorporated
   Google Scholar
• McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425–30
   PubMed Web of Science ®Google Scholar
• Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989;14(2 Suppl 1):14–18
   Google Scholar
• McMahon LP, JK Dawborn. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin follow ing use of recombinant human erythropoietin. Am J Nephrol 1992;12:162–9
   PubMed Web of Science ®Google Scholar
• Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contrib Nephrol 1991;88:81–6; discussion 87–9
   Google Scholar
• Evans RW, Rader B, Manninen DL. The quality of life of hemo-dialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group.[see comment]. JAMA 1990;263:825–30
   Google Scholar
• Moreno F, Aracil FJ, Pérez R, et al. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996;27:548–56
   Google Scholar
• Anonymous. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990;300:573–8
   PubMed Web of Science ®Google Scholar
• Auer J, Simon G, Stevens J, et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 1992;12:40–2
   PubMed Web of Science ®Google Scholar
• Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989;9:25–31
   PubMed Web of Science ®Google Scholar
• Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994;3:329–38
   PubMed Web of Science ®Google Scholar
• Akizawa T, Koshikawa S, Takaku F, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan. Int J Artific Organs 1988;11:343–50
   PubMed Web of Science ®Google Scholar
• Bommer J, Alexiou C, Muller-Buhl U, et al. Recombinant human erythropoietin therapy in haemodialysis patients – dose determination and clinical experience. Nephrol Dial Transplant 1987;2:238–42
   Google Scholar
• Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed) 1987;295:1017–20
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992–1000
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. [see comment]. N Engl J Med 1987;316:73–8
   Google Scholar
• Schaefer RM, Kuerner B, Zech M, et al. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin. Int J Artif Organs 1988;1:249–54
   Google Scholar
• Sobota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials. Contrib Nephrol 1989;76:166–78; discussion 212–8
   Google Scholar
• Suzuki M, Hirasawa Y, Hirashima K, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 1989;76:179–92; discussion 212–18
   Google Scholar
• Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175–8
   PubMed Web of Science ®Google Scholar
• Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Transplant Proc 1991;23:1825–6
   PubMed Web of Science ®Google Scholar
• Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990;89:432–5
   PubMed Web of Science ®Google Scholar
• Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992;60:390–6
   PubMed Web of Science ®Google Scholar
• Sikole A, Polenakovic M, Spirovska V, et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993;17:977–84
   PubMed Web of Science ®Google Scholar
• Morris KP, Sharp J, Watson S, et al. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anemia. Arch Dis Childh 1993;69:580–6
   PubMed Web of Science ®Google Scholar
• Grimm G, Stockenhuber F, Schneeweiss B, et al. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 1990;38:480–6
   PubMed Web of Science ®Google Scholar
• Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 1991;229:125–30
   PubMed Web of Science ®Google Scholar
• Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989;14:486–95
   PubMed Web of Science ®Google Scholar
• Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108–14
   PubMed Web of Science ®Google Scholar
• Revicki, DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–54
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients, J Am Soc Nephrol 1999;10:2392–5
   Google Scholar
• Vanrenterghem Y, Barany P, Mann J. Novel ESP (NESP) maintains hemoglobin (Hb) in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol 1999;10:270A
   Google Scholar
• Locatelli F, et al. Novel ESP for treatment of anemia in chronic renal insufficiency. Kidney Int, 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31:721–7
   PubMed Web of Science ®Google Scholar
• Sonn U, Frandin K, Grimby G. Instrumental activities of daily living related to impairments and functional limitations in 70-year-olds and changes between 70 and 76 years of age. Scand J Rehabil Med 1995;27: 119–28
   Google Scholar
• Whittle H, Goldenberg D. Functional health status and instrumental activities of daily living performance in noninstitutionalized elderly people. J Adv Nurs 1996;23:220–7
   PubMed Web of Science ®Google Scholar
• Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13–19
   Web of Science ®Google Scholar
• Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811–19
   PubMed Web of Science ®Google Scholar
• Hays RD, Sherbourne CD, Mazel R. User’s Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life, RAND Monograph Report, Santa Monica: RAND, 1995
   Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 1993;11:570–9
   PubMed Web of Science ®Google Scholar
• Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol 2001;21:190–203
   PubMed Web of Science ®Google Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658–66
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Vekeman F, Sarokhan B, et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006;22:1929–37
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547–61
   PubMed Web of Science ®Google Scholar
• Mayer G, Thum J, Cada EM, et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525–8
   PubMed Web of Science ®Google Scholar
• Robertson HT, Haley NR, Guthrie M, et al. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients.[see comment]. Am J Kidney Dis 1990;15:325–32
   PubMed Web of Science ®Google Scholar
• Metra M, Cannella G, La Canna G, et al. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am J Cardiol 1991;68:1060–6
   PubMed Web of Science ®Google Scholar
• Abu-Alfa A, Sloan L, Charytan C, Sekkarie M, et al. Darbepoetin alfa for improving and maintaining hemoglobin and health-related quality of life (HRQOL) in patients with chronic kidney disease not receiving dialysis. Submitted September 2006 to Am J Nephrol
   Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–98
   PubMed Web of Science ®Google Scholar
• Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286–90
   PubMed Web of Science ®Google Scholar
• Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992;61:21–5
   PubMed Web of Science ®Google Scholar
• Mann JF. Hypertension and cardiovascular effects – long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995;10(Suppl 2):80–4
   PubMedGoogle Scholar
• Eschbach JW, Aquiling T, Haley NR, et al. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992;38(Suppl 1):S98–103
   PubMedGoogle Scholar
• Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardio respiratory effects of amelioration of renal anaemia by erythro poietin [erratum appears in Lancet 1990 Mar 10;335(8689):614]. Lancet 1990;335:489–93
   PubMed Web of Science ®Google Scholar
• Nissenson AR, et al. Anemia is a reversible cause of brain dysfunction in uremic patients. Kidney Int 1990;37:313
   Web of Science ®Google Scholar
• Bahlmann J, Schöter KH, Scigalla P, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 1991;88:90–106
   PubMedGoogle Scholar
• Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999;14(Suppl 2):29–36
   PubMedGoogle Scholar